Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 205,100 shares, an increase of 22.8% from the December 31st total of 166,971 shares. Based on an average daily trading volume, of 106,376 shares, the days-to-cover ratio is currently 1.9 days. Currently, 5.8% of the company’s shares are short sold. Currently, 5.8% of the company’s shares are short sold. Based on an average daily trading volume, of 106,376 shares, the days-to-cover ratio is currently 1.9 days.

Ensysce Biosciences Stock Performance

Shares of Ensysce Biosciences stock traded down $0.07 during trading on Tuesday, hitting $0.64. 115,077 shares of the stock traded hands, compared to its average volume of 111,354. The stock has a market cap of $2.32 million, a P/E ratio of -0.10 and a beta of 1.17. The company has a fifty day moving average price of $1.15 and a two-hundred day moving average price of $1.80. Ensysce Biosciences has a twelve month low of $0.61 and a twelve month high of $6.60.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.44). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.70 million. Ensysce Biosciences had a negative return on equity of 437.31% and a negative net margin of 244.47%. On average, equities research analysts expect that Ensysce Biosciences will post -8.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Ensysce Biosciences

Several hedge funds have recently made changes to their positions in the stock. TRU Independence Asset Management 2 LLC bought a new stake in Ensysce Biosciences in the 3rd quarter valued at $25,000. Citadel Advisors LLC acquired a new position in Ensysce Biosciences in the third quarter valued at about $34,000. Finally, Virtu Financial LLC acquired a new position in shares of Ensysce Biosciences in the 3rd quarter worth approximately $34,000. Institutional investors own 5.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Ensysce Biosciences to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.